Jordan Allard

Jordan Allard

Auto-generated profile, based on publicly available information

Jordan Allard

Team “Cell Dynamics, Immunity, Metabolism, and Cancer,” Institute for Advanced Biosciences, University Grenoble Alpes, U1209, Institut National de la Santé et de la Recherche Médicale (INSERM), UMR5309, Centre National de la Recherche Scientifique (CNRS), Grenoble 38000, France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Science Advances
Verified
Journal Article
Open access
LBLauriane Bosc
Lauriane Bosc
MPMaria Elena Pero
Maria Elena Pero
David BalayssacDavid Balayssac
David Balayssac
NJNathalie Jacquemot
Nathalie Jacquemot
JAJordan Allard
Jordan Allard
LLLaurence Lafanechère
Laurence Lafanechère
While advances in cancer therapy have improved remission rates, chemotherapy-induced peripheral neuropathy (CIPN) remains a lasting and untreatable side effect. This study introduces Carba1, a bifunctional carbazole compound that protects against CIPN through two mechanisms. First, Carba1 interacts with tubulin, allowing for lower doses of taxanes, common chemotherapeutics known for causing CIPN, without reducing their anticancer effectiveness. Second, Carba1 activates nicotinamide phosphoribosyltransferase (NAMPT), enhancing NAD biosynthesis and boosting the metabolic resilience of neurons and Schwann cells against chemotherapy-induced damage. Carba1 shows strong neuroprotective effects in vitro against paclitaxel, cisplatin, and bortezomib toxicity and in vivo in a rat model of paclitaxel-induced neuropathy. Crucially, Carba1 does not interfere with paclitaxel’s tumor-fighting ability or promote tumor growth. Structure-activity analyses of Carba1 derivatives reveal the potential to develop compounds with dual or solely neuroprotective effects. These findings position Carba1 as a promising candidate to prevent CIPN, with potential to enhance both cancer treatment outcomes and patients’ quality of life.

25 June 2026 in Genes & Development
Verified
Journal Article
Closed access
ALAnthony Lucas
Anthony Lucas
FAFlorence Appaix
Florence Appaix
JAJordan Allard
Jordan Allard
MMMarie Mével-Aliset
Marie Mével-Aliset
ARAnca G. Radu
Anca G. Radu
CTChantal Thibert
Chantal Thibert
How the energy status of enteric progenitors controls neurogliogenesis and the subsequent formation of the complex enteric nervous system (ENS) remains poorly understood. We previously showed that the tumor suppressor kinase LKB1 is essential for postnatal ENS maintenance through amino acid homeostasis. Here, we investigated LKB1's functions during embryonic ENS formation using a genetically engineered mouse model with conditional Lkb1 inactivation in neural crest progenitors during gut colonization. Using advanced 3D imaging techniques on cleared tissue including light sheet microscopy and adaptive optics confocal microscopy, we found that Lkb1 loss impairs early neuronal differentiation followed by progressive glial degeneration, leading to hypoganglionosis and compromised digestive tissue integrity. Notably, Lkb1 inactivation induced a transient upregulation of the glial stress marker S100β during gestation, suggestive of a reactive glial state preceding glial loss. Consistent with this response, Lkb1 loss elevated oxidative stress in the digestive tract and in neural crest progenitors and their glial derivatives, triggering DNA damage and p53 activation. Although p53 ablation rescued glial specification in vitro and glial maintenance in vivo, it only partially restored ENS architecture in vivo without rescuing enteric neuron numbers. Together, these findings establish LKB1 as a critical metabolic checkpoint governing neuronal–glial balance during ENS development and suggest that dysregulated LKB1 signaling may contribute to human enteric neurogliopathies.